ILC Therapeutics

ILC Therapeutics is a pre-clinical biotechnology company developing hybrid interferons, an engineered cytokine drug class combining favourable attributes of multiple naturally occurring interferon subtypes.

The platform rationally designs novel candidates with reduced toxicity and pleiotropic activity across multiple disease targets.

The lead programme is a broad-spectrum antiviral for respiratory viral infections including RSV.

Further programmes address atopic dermatitis in humans and, through an R&D partnership with Dechra Pharmaceuticals, canine atopic dermatitis.